A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of LOP628, Administered Intravenously in Adult Patients With cKit-positive Tumors and Acute Myeloid Leukemia

Trial Profile

A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of LOP628, Administered Intravenously in Adult Patients With cKit-positive Tumors and Acute Myeloid Leukemia

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs LOP 628 (Primary)
  • Indications Acute myeloid leukaemia; Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 28 Sep 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 12 Mar 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
    • 15 Jan 2015 Planned End Date changed from 1 Nov 2017 to 1 Jun 2020 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top